Dr Reddy's launches antibiotic drug in US market

Tags: Companies
Dr Reddy's Laboratories Ltd has launched Moxifloxacin Hydrochloride tablets in the US market for the treatment of a wide range of diseases, including pneumonia, bronchitis and skin infections.

The drug was launched yesterday following the approval by the United States Food & Drug Administration (USFDA), DRL said in a press release today.

The tablets, a generic version of Avelox 400 mg, are available in bottle counts of 30, it said.

Bayer's Avelox is indicated for the treatment of community acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS), uncomplicated and complicated skin and skin structure infections (uSSSI and cSSSI), mild to moderate pelvic inflammatory disease (PID), and complicated intra-abdominal infections (cIAI), according to Avelox official website.

According to IMS Health, Avelox (moxifloxacin HCl) tablets had a sales figure of approximately $195 millions in 2013, the release said.

Shares of DRL were trading at Rs 2,800 apiece on the BSE during afternoon trade.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Child abuse needs to be tackled with the seriousness it deserves

    The Bangalore rape case has again brought into focus an issue we Indians forever shy away from facing up to — child sexual abuse.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Varun Dutt

<b>Riskfactor</b>: THE BASE RATE BIAS

Base rate fallacy, also called base rate neglect or base ...

Parvez Imam

Revisiting history can do us all good

We often think that we understand history. We read it ...

Bubbles Sabharwal

Your happiness doesn’t depend on your needs

They are two different words (and even worlds) altogether: having ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture